Colin John Meyer MD MBA

Other MD/DO•Plano, TX

Chief Research and Development Officer, Reata Pharmaceuticals, Inc.

Join to View Full Profile

Reata Pharmaceuticals, Inc.5320 Legacy Drive PlanoPlano, TX 75024
Phone+1 972-865-2200

Education & Training

University of Texas Southwestern Medical SchoolClass of 2003

Certifications & Licensure

DE State Medical License 2020 - 2027
MD State Medical License 2025 - 2025
MA State Medical License 2019 - 2020

Clinical Trials

Study to Assess the Safety, Tolerability, and Pharmacodynamics of RTA 402 in Patients With Hepatic Dysfunction Start of enrollment: 2007 Apr 30
Terminated
Phase 1, Phase 2
Bardoxolone Methyl Evaluation in Patients With Chronic Kidney Disease and Type 2 Diabetes Start of enrollment: 2011 Jun 30
Terminated
Phase 3
A Single-Dose, Open-Label, Randomized, Food Effect and Blinded, Randomized, Dose Proportionality Study in Healthy Volunteers With Bardoxolone Methyl Start of enrollment: 2011 Oct 31
Completed
Phase 1
A Phase I Study to Investigate the Absorption, Metabolism and Excretion in Healthy Male Subjects Start of enrollment: 2011 Dec 01
Completed
Phase 1
Pharmacokinetic and Pharmacodynamic Study of Bardoxolone Methyl in Patients With Chronic Kidney Disease and Type 2 Diabetes Start of enrollment: 2012 Apr 30
Terminated
Phase 1
Pilot Assessment of the Effects of Bardoxolone Methyl on Renal Perfusion, Systemic Haemodynamics and Cardiac Function in Patients With Chronic Kidney Disease and Type 2 Diabetes Start of enrollment: 2012 Apr 30
Withdrawn
Phase 1
Single-Dose, Open-Label Pharmacokinetic Study of Bardoxolone Methyl in Subjects With Mild, Moderate, and Severe Hepatic Impairment and Normal Hepatic Function Start of enrollment: 2012 Apr 30
Completed
Phase 1
A Double-Blind, Randomized, Placebo-Controlled Safety Study Evaluating the Effects of Residual Renal Function (RFF) in Patients With End-Stage Renal Disease and Type 2 Diabetes Mellitus on Peritoneal Dialysis Start of enrollment: 2012 Jul 31
Withdrawn
Phase 2
Join now to see all

Publications & Presentations

PubMed

26 citations
Safety and efficacy of omaveloxolone in patients with mitochondrial myopathy (MOTOR trial).
Karen Lindhardt Madsen, Astrid Emilie Buch, Bruce H. Cohen, Marni J. Falk, Angela Goldsberry
Neurology. 2020-01-02
30 citations
Effect of bardoxolone methyl on the urine albumin-to-creatinine ratio in patients with type 2 diabetes and stage 4 chronic kidney disease.
Peter Rossing, Geoffrey A. Block, Melanie P. Chin, Angie Goldsberry, Hiddo J.L. Heerspink
Kidney International. 2019-10-01
30 citations
Bardoxolone methyl analog attenuates proteinuria-induced tubular damage by modulating mitochondrial function
Hajime Nagasu, Yuji Sogawa, Kengo Kidokoro, Seiji Itano, Toshiya Yamamoto
FASEB Journal. 2019-08-30

Press Mentions

Bob Goeltz Bolts Unity Biotechnology to Become CFO at Arcus Biosciences; John Johnson Tapped for His Latest CEO GigJuly 10th, 2020
Bardoxolone Methyl Improved Kidney Function in Patients with Autosomal Dominant Polycystic Kidney Disease and IgA Nephropathy in the Ongoing Phase 2 Phoenix StudyMay 25th, 2018

Colin John Meyer MD MBA

Dr. Meyer is on Doximity

Education & Training

Certifications & Licensure

Clinical Trials

Publications & Presentations

Press Mentions

Viewing the full profile is available to verified healthcare professionals only.